Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) by Year
CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%) (%)
Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel): 71.6% in FY2025, down 13.6 pts from a year earlier.
Where the FY2025 figure comes from
“|| US | 1,492 | 869 | 71.6 | 71.6 | —”
Source: Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | CARVYKTI (ciltacabtagene autoleucel) — U.S. operational growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 28, 2025 | 71.6% | -13.6 pts | Form 8-K (a2025q4exhibit991.htm, filed 2026-01-21) ↗ |
| FY2024 | Dec 29, 2024 | 85.2% | – | Form 8-K (a2024q4exhibit991.htm, filed 2025-01-22) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson CARVYKTI (ciltacabtagene autoleucel) (%), annual FY2024–FY2025 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-carvykti-us-ops-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.